Sinopsis
New and exciting data presented each day during the conference and address the potential impact on current clinical practice.
Episodios
-
![Jennifer R. Brown, MD, PhD: Update on PI3K inhibitors: Idelalisib, copanlisib, duvelisib, umbralisib: Is toxicity the key?]()
Jennifer R. Brown, MD, PhD: Update on PI3K inhibitors: Idelalisib, copanlisib, duvelisib, umbralisib: Is toxicity the key?
31/10/2018 Duración: 18minWebcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice
-
![John C. Byrd, MD: Update on BTK inhibitors: Ibrutinib pus the new kids on the block: Are they better?]()
John C. Byrd, MD: Update on BTK inhibitors: Ibrutinib pus the new kids on the block: Are they better?
31/10/2018 Duración: 21minWebcast: Navigating the Evolving Therapeutic Landscape of CLL: Strategies for the Optimal Application of Emerging Agents and Combinations in Practice
-
![Jesús F. San Miguel, MD: Keynote lecture: Is myeloma curable?]()
Jesús F. San Miguel, MD: Keynote lecture: Is myeloma curable?
31/10/2018 Duración: 17minWebcast: New Horizons in the Treatment of Relapsed and Refractory Myeloma
-
![Kenneth C. Anderson, MD: New horizons in the treatment of relapsed and refractory myeloma]()
Kenneth C. Anderson, MD: New horizons in the treatment of relapsed and refractory myeloma
31/10/2018 Duración: 19minWebcast: New Horizons in the Treatment of Relapsed and Refractory Myeloma
-
![Cara A. Rosenbaum, MD: Management of the unfit and frail patient]()
Cara A. Rosenbaum, MD: Management of the unfit and frail patient
31/10/2018 Duración: 24minWebcast: New Horizons in the Treatment of Relapsed and Refractory Myeloma
-
![Adriana C. Rossi, MD: Management of a fit patient: Induction, which one to choose, 3 or 4 drugs]()
Adriana C. Rossi, MD: Management of a fit patient: Induction, which one to choose, 3 or 4 drugs
31/10/2018 Duración: 20minWebcast: New Horizons in the Treatment of Relapsed and Refractory Myeloma
-
![Ajai Chari, MD: DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - No]()
Ajai Chari, MD: DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - No
31/10/2018 Duración: 14minWebcast: Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment?
-
![C. Ola Landgren, MD, PhD: DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes]()
C. Ola Landgren, MD, PhD: DEBATE: Is MRD the new primary goal for multiple myeloma treatment? - Yes
31/10/2018 Duración: 16minWebcast: Looking for One in a Million: Is MRD the New Primary Goal for Multiple Myeloma Treatment?
-
![Koen von Besien, MD, PhD: AML 60-80 years: Who should get an allo transplant?]()
Koen von Besien, MD, PhD: AML 60-80 years: Who should get an allo transplant?
31/10/2018 Duración: 20minWebcast: FLT3 Targets in R/R AML: Evaluating Emerging Clinical Data and Implications on Current Practice
-
![Gail J. Roboz, MD: MRD in AML: What is it and what do I do about it?]()
Gail J. Roboz, MD: MRD in AML: What is it and what do I do about it?
31/10/2018 Duración: 24minWebcast: FLT3 Targets in R/R AML: Evaluating Emerging Clinical Data and Implications on Current Practice
-
![Sangmin Lee, MD: AML: What to do with your 500-gene mutation report]()
Sangmin Lee, MD: AML: What to do with your 500-gene mutation report
31/10/2018 Duración: 17minWebcast: FLT3 Targets in R/R AML: Evaluating Emerging Clinical Data and Implications on Current Practice
-
![Gail J. Roboz, MD: Newly diagnosed AML: Hitting the right target]()
Gail J. Roboz, MD: Newly diagnosed AML: Hitting the right target
31/10/2018 Duración: 29minWebcast: FLT3 Targets in R/R AML: Evaluating Emerging Clinical Data and Implications on Current Practice
-
![Koen von Besien, MD, PhD: Which patients should be transplanted for ALL?]()
Koen von Besien, MD, PhD: Which patients should be transplanted for ALL?
31/10/2018 Duración: 24minWebcast: New and Emerging Agents in ALL and the Evolving Treatment Paradigm
-
![Pinkal Desai, MD: Immunotherapy of ALL]()
Pinkal Desai, MD: Immunotherapy of ALL
31/10/2018 Duración: 29minWebcast: New and Emerging Agents in ALL and the Evolving Treatment Paradigm
-
![Pinkal Desai, MD: Diagnosis and treatment of newly diagnosed ALL]()
Pinkal Desai, MD: Diagnosis and treatment of newly diagnosed ALL
31/10/2018 Duración: 20minWebcast: New and Emerging Agents in ALL and the Evolving Treatment Paradigm
-
![Millie D. Long, MD, MPH, FACG: IBD Case #2: Preventive care needs in an older adult patient]()
Millie D. Long, MD, MPH, FACG: IBD Case #2: Preventive care needs in an older adult patient
23/10/2018 Duración: 06minWebcast: Time for Action: The Urgent Need for Immunization in Patients with IBD
-
![Millie D. Long, MD, MPH, FACG: IBD Case #1: Preventive care needs in a young patient]()
Millie D. Long, MD, MPH, FACG: IBD Case #1: Preventive care needs in a young patient
23/10/2018 Duración: 19minWebcast: Time for Action: The Urgent Need for Immunization in Patients with IBD
-
![Francis A. Farraye, MD, MSc, FACG: Emerging therapies and immunizations for IBD patients]()
Francis A. Farraye, MD, MSc, FACG: Emerging therapies and immunizations for IBD patients
23/10/2018 Duración: 20minWebcast: Time for Action: The Urgent Need for Immunization in Patients with IBD
-
![Gil Y. Melmed, MD, MS, FACG: Vaccination guidelines and recommendations in IBD]()
Gil Y. Melmed, MD, MS, FACG: Vaccination guidelines and recommendations in IBD
23/10/2018 Duración: 24minWebcast: Time for Action: The Urgent Need for Immunization in Patients with IBD
-
![Ghassan Abou-Alfa, MD: Hepatocellular Carcinoma: A Guide to Integrating Emerging Therapies into Current Treatment Paradigms]()
Ghassan Abou-Alfa, MD: Hepatocellular Carcinoma: A Guide to Integrating Emerging Therapies into Current Treatment Paradigms
01/09/2018 Duración: 55minWebcast: Hepatocellular Carcinoma: A Guide to Integrating Emerging Therapies into Current Treatment Paradigms
